Europe Home Infusion Therapy Market Outlook and Forecast 2025-2033

Europe Home Infusion Therapy Market Size & Forecast 2025-2033

The Europe Home Infusion Therapy Market is anticipated to grow to US$ 21.85 billion by 2033, growing from US$ 13.08 billion in 2024, at a CAGR of 5.87% for the period from 2025 to 2033. Growth is driven by the growing incidence of chronic conditions, aging populations, and growing needs for cost-efficient, home-based treatments. Healthcare policies supporting the growth of infusion devices also fuel the growth of the market in Europe.

Europe Home Infusion Therapy Market Outlook

Home infusion therapy is the delivery of drugs, nutrients, or fluids directly into a patient's bloodstream through intravenous (IV) or subcutaneous routes, all at home. It is done under medical observation and normally consists of treatments like antibiotics, antivirals, chemotherapy, pain relief, parenteral nutrition, and hydration therapy.

The main purpose of home infusion therapy is to provide patients with a convenient, cost-effective, and safe alternative to hospital care. It is particularly valuable for those with chronic diseases, like cancer, autoimmune conditions, or infection needing prolonged IV therapy. Home environments provide patients with a higher quality of life, decrease the chances of hospital-acquired infections, and decrease total healthcare expenses.

Growth Drivers for the Europe Home Infusion Therapy Market

Increased Incidence of Chronic and Age-Related Conditions

Europe's aging population is resulting in a greater number of patients with chronic conditions like cancer, diabetes, immune deficiencies, and infections that need long-term intravenous therapy. Home infusion therapy enables such patients to undergo treatment in the comfort of their own homes, enhancing quality of life and treatment compliance. Since the elderly population is on the rise, the demand for affordable, home-based care options such as infusion therapy is likely to increase throughout the region. In terms of actual causes of death, chronic diseases such as cancer, cardiovascular disease, chronic respiratory disease, diabetes, and mental illness account for 85% of deaths in the EU. Cancer resulting from all causes is the leading cause of mortality under the age of 65, while cardiovascular disease is the leading cause of mortality after the age of 65.

Cost-Effectiveness and Hospitalization Decrease

European healthcare systems are under stress to cut down on hospital overcrowding and expense. Home infusion therapy provides a cost-saving option by decreasing inpatient stays without diminishing the quality of treatment. It reduces the risk of hospital-borne infections and allows patients to heal in a comfort zone. With encouraging government policies and payers interested in minimizing healthcare spending, the transition to therapies at home is turning into a long-term trend in Europe. The planned centralised Health Technology Assessment system in 2025, as well as the 2023 renovation of the EU pharmaceutical law, will help create a more favorable climate for healthcare innovation to create an even more innovative, and competitive market.

Technological Progress and Telemonitoring

Technological progress in portable infusion pumps, intelligent IV systems, and telemonitoring technologies has greatly improved the efficacy and safety of home infusion therapy. Patients can be remotely monitored in real-time by healthcare professionals, allowing for quick response to complications. These advancements have boosted patient confidence and physician acceptance, further driving market growth and greater access to cutting-edge therapies beyond traditional clinical environments. April 2022, JMS Co., Ltd. reported that its "JMS Tongue Pressure Measurement Device" has been certified under the European Medical Device Regulation (EU-MDR).

Difficulties in the Europe Home Infusion Therapy Market

Variability in Reimbursement and Healthcare Policy

Another major issue in the European home infusion therapy market is the absence of standardized reimbursement systems within countries. Whereas countries such as Germany and France provide strong support for home care, others are behind, resulting in uneven access. These disparities restrict the growth of home infusion services, particularly in Eastern Europe, and make it difficult for multinational providers to operate uniformly across the continent.

Shortage of Qualified Healthcare Professionals

Trained nurses and healthcare professionals are needed to provide therapies and ensure patient safety with home infusion therapy. Europe is experiencing an escalating shortage of qualified personnel, especially in rural or underserved communities. Such a shortage may result in delays in services, decreased options for therapy, and decreased patient satisfaction. Proper training and workforce expansion are necessary to expand home infusion services effectively and sustain quality care.

Europe Home Infusion Pump Market

The infusion pump segment is a bedrock of Europe's home infusion therapy market, providing safe and accurate drug delivery. Contemporary portable pumps are light, programmable, and easy to use, making patients responsible for administering long-term therapies at home. Advances in technology, including wireless communications and intelligent dosage management, improve the safety and adherence of patients. Increasing need for managing chronic diseases as well as post-operative treatment continues to drive the market for infusion pumps used at home.

Europe Home Infusion IV Cannulas Therapy Market

IV cannulas are crucial to home infusion therapy by ensuring safe vascular access for the delivery of medication. In Europe, the demand is increasing with more cases of infections, cancer, and immune deficiency needing intravenous therapy. Manufacturers are keen on creating safety-oriented cannulas to avoid complications. The growth of outpatient facilities and the inclination towards home therapies are driving the growth of this necessary consumable segment.

Europe Anti-Infective Home Infusion Therapy Market

Anti-infective treatment, specifically intravenous antibiotics and antifungals, is among the top uses in the European home infusion therapy market. It's widely utilized for the treatment of infections like osteomyelitis, cellulitis, or postoperative complications. European hospitals and healthcare systems are transferring eligible patients to home care to decrease inpatient volumes. As antimicrobial resistance continues to rise, the requirement for extended, supervised antibiotic therapy in the home environment is continually growing.

Europe Chemotherapy Home Infusion Therapy Market

Home chemotherapy provides cancer patients with ease and comfort of accessing life-extending treatment away from hospital environments. In Europe, this market is expanding because of enhanced oncology practices, infusion pump technologies, and support systems. Hospital visits and infections are avoided through chemotherapy at home, and it is the preferred treatment modality for immunocompromised patients. The UK and France are scaling up pilot programs and guidelines to include home-based oncology in national cancer care plans.

Germany Home Infusion Therapy Market

Germany boasts one of the most developed home infusion therapy markets in Europe, underpinned by a strong healthcare system and beneficial reimbursement policies. The nation enjoys ubiquitous availability of infusion equipment, skilled nursing, and home care services. Anti-infectives, parenteral nutrition, and pain management therapies are prevalent. Technological advancement and government investment in home healthcare services continue to drive growth and patient acceptance throughout Germany.

United Kingdom Home Infusion Therapy Market

Home infusion therapy is being increasingly encouraged by the UK's National Health Service (NHS) to minimize hospital stays and expenses. Therapies such as intravenous antibiotics, chemotherapy, and hydration services provided at home are becoming more in demand. Advances in remote monitoring and infusion pumps facilitate wider adoption. Although workforce shortages pose challenges, strategic investment and public-private collaborations are assisting the UK in developing its home-based treatment capacity. May 2025 - BD, the world's leading medical technology company, is launching BD neXus, a next-generation infusion pumps and IV sets and medication management software suite, in the UK & Ireland.

Russia Home Infusion Therapy Market

Russia's home infusion therapy industry is evolving, with increased interest in developing access outside major metropolitan areas. Economic reform and the modernization of healthcare services have created possibilities for home care, particularly for chronic disease and post-op care. Challenges remain, including a shortage of skilled staff and uneven regional infrastructure. With enhanced awareness and investment, Russia's home infusion industry has solid long-term prospects.

France Home Infusion Therapy Market

France boasts a mature home infusion therapy infrastructure, underpinned by state-funded healthcare and an extensive home care network. Anti-infectives, chemotherapy, and parenteral nutrition are typical therapies. France enjoys the benefits of cutting-edge medical technology, reimbursements, and very high patient awareness. Public sector hospitals frequently collaborate with private-sector infusion service providers to create seamless at-home treatment, propelling ongoing market growth and innovation.

Market Segmentation

Product

• Infusion Pump
• Intravenous Sets
• IV Cannulas
• Needleless Connectors

Application

• Anti-Infective
• Hydration Therapy
• Chemotherapy
• Enternal Nutrition
• Parenteral Nutrition
• Specialty Pharmaceuticals
• Others

Country

• France
• Germany
• Italy
• Spain
• United Kingdom
• Belgium
• Netherlands
• Russia
• Poland
• Greece
• Norway
• Romania
• Portugal
• Rest of Europe

All companies have been covered with 5 Viewpoints

• Overviews
• Key Person
• Recent Developments
• SWOT Analysis
• Revenue Analysis

Key Players Analysis

• Pfizer Inc.
• Smith & Nephew plc
• Terumo Corporation
• Johnson & Johnson Services, Inc.
• Becton, Dickinson and Company
• Baxter International Inc.
• ICU Medical
• Eli Lilly and Company